Sound excitable drugs

声音兴奋药物

基本信息

批准号：
8322846
负责人：
CHING-HSUAN TUNG
金额：
$ 30.49万
依托单位：
METHODIST HOSPITAL RESEARCH INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-09-01 至 2014-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8322846
关键词：
Ablation Adenocarcinoma Affect Aleurites Apoptotic Area Cancer cell line Carcinoma Cell Culture Techniques Cells Cessation of life Chemicals Clinical Cytotoxic agent Development Disease Dose Drug Design Evaluation Experimental Designs Fibroblasts Focused Ultrasound Therapy Future Generations Glioma Goals Image Lead Light Liver Malignant Bone Neoplasm Malignant Neoplasms Malignant neoplasm of brain Malignant neoplasm of pancreas Mus Necrosis Neuroblastoma Optics Pathway interactions Pharmaceutical Preparations Photochemotherapy Phototoxicity Porphyrins Principal Investigator Process Radiation Radiation therapy Reaction Time Reactive Oxygen Species Renal Cell Carcinoma Renal carcinoma Reporter Research Safety Series Side Site Structure Technology Therapeutic Tissues Toxic effect Translations Ultrasonic wave Ultrasonography Uterine Fibroids Xanthenes alternative treatment base cancer cell cancer therapy cell killing chemotherapeutic agent chemotherapy clinical practice cytotoxic cytotoxicity design in vivo innovation killings neoplastic cell novel physical property programs public health relevance research study sound tumor

项目摘要

DESCRIPTION (provided by applicant): A novel type of therapeutic drugs which could be selectively activated by locally applied ultrasound is proposed to treat cancer and other disease. The technology is termed sonochemotherapy. The proposed sound excitable drugs (SED) are designed to have neither cytotoxicity nor phototoxicity in their native states, but having ultrasound inducible cytotoxicity. Ultrasound is a mature, safe and non-radiation technology, routinely used in various clinical imaging and treatments. Combining ultrasound with the proposed SED, the applied ultrasound wave could become a drug activator, converting non-toxic SED into cytotoxic agents to treat diseases at defined area. Different from conventional nonspecific chemotherapy, which has cytotoxic drugs circulating through out the body, sonochemotherapy provide site-specific chemotherapeutic effect. Ultrasound penetrates deep tissue emitting no radiation, thus the proposed sonochemotherapy is expected to become an alternative treatment approach of radiation therapy and photodynamic therapy with superior efficacy and safety. PUBLIC HEALTH RELEVANCE: The goal of this research is to develop a new type of tunable chemotherapeutic agents which could only be activated by specific sound wave. The proposed sonochemotherapeutic technology is unique and could have great potential in cancer treatment. If successful, it could become a safe substitute to currently used radiation therapy.

描述（由申请人提供）：提出了一种可以通过局部施加超声波选择性激活的新型治疗药物来治疗癌症和其他疾病。该技术称为声化学疗法。所提出的声音兴奋药物（SED）被设计为在其天然状态下既不具有细胞毒性也不具有光毒性，但具有超声诱导的细胞毒性。超声是一种成熟、安全、非辐射的技术，常用于各种临床影像和治疗。将超声波与拟议的 SED 相结合，所应用的超声波可以成为药物激活剂，将无毒的 SED 转化为细胞毒性剂，以治疗特定区域的疾病。与传统的非特异性化疗不同，传统的非特异性化疗使用细胞毒性药物在体内循环，声化疗提供部位特异性化疗效果。超声波穿透深层组织，不发出辐射，因此所提出的声化学疗法有望成为放射疗法和光动力疗法的替代治疗方法，具有卓越的疗效和安全性。公共健康相关性：这项研究的目标是开发一种只能由特定声波激活的新型可调化疗药物。所提出的声化学治疗技术是独特的，在癌症治疗方面具有巨大的潜力。如果成功，它可能成为目前使用的放射治疗的安全替代品。